A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Celgene
Dana-Farber Cancer Institute
Qilu Pharmaceutical Co., Ltd.
University of Miami
Children's Hospital Medical Center, Cincinnati
Massachusetts General Hospital
Fondazione Italiana Linfomi - ETS
Karyopharm Therapeutics Inc
Dana-Farber Cancer Institute
Massachusetts General Hospital
Karyopharm Therapeutics Inc
Qilu Pharmaceutical Co., Ltd.
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Assistance Publique - Hôpitaux de Paris